Chronic Kidney Disease
CVrg’s extensive coverage of Chronic Kidney Disease, including the subindications of diabetic nephropathy, primary nephropathies, renal anemia, hyperphosphatemia, hyperkalemia, secondary hyperparathyroidism, acute kidney injury, and end stage renal disease, provides comprehensive coverage of this complicated landscape and marketplace.
Therapy Area Director, CKD
Jennifer received her Ph.D. in Biomedical Sciences from the University of California, San Francisco and postdoctoral training at Stanford University’s School of Medicine before joining CVrg. In addition to her solid technical foundation, she brings strong analytic abilities and strategic planning experience as well as communication, writing and presentation skills to her leadership role in our CKD area.
Melissa Popowski, Ph.D.
Disease Area Analyst, CKD
Melissa received her Ph.D in Cellular and Molecular Biology at the University of Texas at Austin and completed her postdoctoral work at the Rockefeller University. She is a cross-disciplinary researcher with biotech experience who brings her knowledge of fundamental biology and understanding of the regulatory landscape together to create meaningful insights for CVrg’s clients.
Christa Trexler, Ph.D.
Disease Area Analyst, CKD
Christa received her PhD in Molecular Biology from the University of Colorado Boulder, followed by postdoctoral training at the University of California San Diego. In addition to her strong research experience, she excels at communicating complex scientific topics to a variety of audiences.
|CVrg Market Strategies™||
ChronicKidneyDisease, 2020–2029 is a cutting-edge detailed market research report with unmatched scope, depth, and accuracy. This best-in-class resource provides a highly granular assessment of new product development, emerging trends, unmet needs, epidemiology, current treatment and market landscapes.
KOL comments, SWOTs, clinical trial tracking, estimations of launch dates and target patient populations are included for products ≥Ph 2 along with regional coverage of USA, EU5, and Japan. Fresh new data and analytical observations gained throughout the year in CKD from CVrg Sentinel, Conference, Insights and Advisory research are also included.
CVrg continuously monitors how new scientific, clinical, regulatory and market developments are changing the commercial potential of CKD assets. This monthly delivery informs clients about what is happening in the marketplace and how it might affect their products.
CVrg keeps abreast of cutting edge clinical data by attending cardio-metabolic congresses such as ADA, ESC, ASN and AHA. Our experts carefully analyze the new data presented and deliver incisive, presentation-style reports informing subscriber organizations about what’s new, what’s important, and why.
|CVrg KOL Insights™||
CVrg experts conduct primary research with KOLs in CKD, using their critical eyes to evaluate emerging trends, pipeline products and implications for the field. Clients may review and add to our “omnibus” discussion guides and receive detailed reports and presentations focused on answering the most pressing issues they face today.
answers & new content
CVrg is uniquely positioned to deliver quick, thorough and reliable answers to non-proprietary questions in CKD drug markets. We are immediately equipped with comprehensive data and put our best methodologies and efforts behind each inquiry so clients receive the most accurate insight possible within a given timeframe.